



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/144237/>

Version: Accepted Version

Article:

Di Martino, E, Ali, M and Inglehearn, CF (2019) Matrix metalloproteinases in keratoconus - too much of a good thing? *Experimental Eye Research*, 182. pp. 137-143. ISSN: 0014-4835

<https://doi.org/10.1016/j.exer.2019.03.016>

© 2019 Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Accepted Manuscript

Matrix metalloproteinases in keratoconus – Too much of a good thing?

Erica di Martino, Manir Ali, Chris F. Inglehearn

PII: S0014-4835(18)30796-6

DOI: <https://doi.org/10.1016/j.exer.2019.03.016>

Reference: YEXER 7624

To appear in: *Experimental Eye Research*


Received Date: 29 November 2018

Revised Date: 27 February 2019

Accepted Date: 19 March 2019

Please cite this article as: di Martino, E., Ali, M., Inglehearn, C.F., Matrix metalloproteinases in keratoconus – Too much of a good thing?, *Experimental Eye Research* (2019), doi: <https://doi.org/10.1016/j.exer.2019.03.016>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Matrix metalloproteinases in keratoconus – too much of a good thing?

Erica di Martino^a, Manir Ali^b, Chris F Inglehearn^b

^a Division of Primary Care, Public Health and Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Worsley Building, Clarendon Way, Leeds, LS2 9NL; ^b Section of Ophthalmology and Neuroscience, Leeds Institute of Medical Research, University of Leeds, Wellcome Trust Brenner Building, Beckett Street, Leeds, LS9 7TF, United Kingdom.

Corresponding author: Chris Inglehearn, Section of Ophthalmology and Neuroscience, Leeds Institute of Medical Research, University of Leeds, Wellcome Trust Brenner Building, Beckett Street, Leeds, LS9 7TF, U.K; e-mail: c.inglehearn@leeds.ac.uk; phone: +44 (0) 113-34-38646

Conflict of interest statement: No conflicts of interest to declare

Keywords: keratoconus, cornea, extracellular matrix, matrix metalloproteases, MMPs

Abstract

Keratoconus (KC) is a progressive, early onset, and often bilateral eye condition, in which the cornea gradually weakens and bulges out, and in advanced cases may eventually become cone shaped. The available evidence suggests that it is a multifactorial disease with environmental and genetic contributions. Matrix Metalloproteinases (MMPs) are a family of 24 zinc-dependent proteases with the ability to degrade collagen and other extracellular matrix (ECM) proteins, which are important components of the cornea. During the past two decades a growing body of evidence has accumulated suggesting a link between MMPs and keratoconus. This article aims to summarize the published literature on the role of MMPs in the pathogenesis of KC. MMP-driven ECM remodelling is thought to be a necessary step for cornea healing, but a fine balance in the expression of MMPs is essential in maintaining the integrity and transparency of the cornea and for its correct healing, and an imbalance in this tightly regulated process may, in the long term, result in the progressive weakening of the cornea. There is extensive evidence that MMPs are upregulated in the corneal tissue and tears of KC patients, implicating dysregulated proteolysis in KC, with an increase in the level of some MMPs, particularly MMP-1 and MMP-9, confirmed in multiple independent studies. There is also evidence for a causative link between inflammation, which could result from the mechanical trauma due to contact lens wearing or/and eye rubbing, and the increased MMP production observed in KC. However, the precise role of specific MMPs in the cornea is still unclear and the mechanisms causing their upregulation are mostly undiscovered. Further studies are required to verify the functional role of specific MMPs in KC development and assess the genetic association between common MMP variants and risk of KC. As MMP inhibitors are in development, this information could potentially drive the discovery of new treatments for KC.

1. Introduction

Keratoconus (KC; from the Greek words kerato meaning cornea and conus meaning cone) is an early onset, progressive and often bilateral eye condition in which the cornea, the clear dome-shaped external layer of the eye, thins and weakens, gradually bulging out and eventually becoming cone-shaped in advanced cases^{1,2}. As the curvature of the cornea has a key role in determining the optical power of the eye, the disease results in blurred vision due to irregular astigmatism and sometimes monocular diplopia and excessive sensitivity to light¹. Mild cases can be corrected with rigid gas-permeable contact lenses and progression can be slowed with collagen crosslinking (CXL)³. However, some patients eventually require a corneal transplant⁴ and KC is still one of the most common indications for keratoplasty worldwide⁵⁻⁷, although the frequency of corneal transplantations for KC patients is declining in some countries⁸. As the average age at onset of the disease is in early adulthood⁹, KC has a long term impact on the quality of life of patients. KC is relatively common, but there is great variation between different countries and ethnicities¹⁰. Prevalence is approximately 1:2000 in the US population¹¹, but a frequency as high as 1:25 has been reported in Middle Eastern populations¹⁰. In the UK, the disease is 4- to 7-fold more common in south Asians than in Caucasians living in the same geographical area^{12,13}. The observed variation in prevalence between different ethnicities, combined with evidence that up to one fifth of KC cases are familial, with multiple generations and members of the same family affected^{1,14,15}, suggests a genetic aetiology for the condition in at least a subset of patients. In an attempt to unravel the genetic causes of KC, a number of candidate-gene, linkage and genome-wide association (GWAS) studies have been performed¹⁶⁻¹⁸. Several genetic variants have been identified^{15,17}, but together these account only for a small increment in disease risk, and explain only a proportion of instances of familial clustering. A number of environmental factors have also been associated with KC risk, including contact lens wearing^{2,19,20}, eye rubbing^{21,22}, hay fever and other forms of atopy^{23,24}. Exposure to UV has also been hypothesized to contribute to the disease²⁵, and could contribute to the higher prevalence of KC in South Asian and Middle Eastern populations¹⁰. Overall, these findings suggest that KC is likely to be a complex disease with a multifactorial aetiology.

Matrix Metalloproteinases (MMPs) are a family of 24 zinc-dependent proteases, involved in physiological processes such as tissue remodeling, embryonic development, wound healing, angiogenesis and inflammation²⁶. Their function is to break down extracellular matrix (ECM) components, thereby modifying tissue architecture, creating spaces for cell migration, and

influencing cell adhesion^{26,27}. They also regulate cell signaling by releasing ECM-bound growth factors, cleaving signaling molecules or modifying interaction between ECM molecules and their receptors on the cell surface^{26,27}. Each MMP has specificity for different and often overlapping substrates²⁸. Historically they have tended to be divided into four general groups, collagenases, gelatinases, stromelysins and membrane-type metalloproteinases, though these groupings are increasingly thought to be overly simplistic²⁷. MMP activity is carefully regulated with both transcriptional and post-transcriptional mechanisms²⁸. Firstly, their expression is generally limited in healthy tissue and transcriptionally upregulated only in response to specific cues²⁸. Secondly, the enzymes are transcribed as inactive zymogens (pro-MMPs) which require post-translational conversion to their catalytically active form²⁸. Finally, the activity of mature MMPs is kept in check by four inhibitory proteins, called Tissue Inhibitors of Metalloproteinases (TIMPs)²⁸. Disruption of these tight regulatory mechanisms results in over-activation of MMPs and pathological ECM degradation, which have been linked to a number of diseases²⁹ including arthritis, cardiovascular disease, periodontal disease, neurodegenerative conditions and cancer. This article reviews the evidence that an imbalance in the activity of MMPs in the cornea may contribute to the development of keratoconus.

2. ECM and MMP alterations in keratoconus

The cornea is composed of five layers (Figure 1): the outer squamous non-keratinized epithelium including the basement membrane, the acellular Bowman's layer, the stroma, the Descemet's membrane, and the endothelium^{1,30}. The stroma normally accounts for around 80-90% of corneal thickness. Its main constituents are highly ordered and organized collagenous lamellae and specialized cells called keratocytes, which secrete the stromal extracellular matrix (ECM) components. The correct composition and strict organization of stromal ECM is essential for corneal refractivity, mechanical strength and stability, including the ability to maintain shape and curvature³¹. Besides collagens, ECM components of the cornea include laminins, fibronectins, thrombospondins, proteoglycans and matrilins^{30,32}.

In KC, a progressive localized thinning of the stromal compartment is observed, often with concomitant variable thinning of the epithelium¹. Examination of KC corneas reveals a reduction in the density of stromal keratocytes and in the thickness of the collagenous lamellae, along with changes in their orientation relative to the Bowman's layer¹. In addition, altered levels of ECM components have been observed. For example, a reduction in expression of collagen types I, III, V

and XII proteins has been found in KC³³. Changes in ECM structure and composition cause a localized thinning and weakening of the cornea, eventually leading to the protrusion and change in shape observed in the disease¹. Collagen crosslinking by treatment with riboflavin and ultraviolet A light can slow down KC progression by improving corneal biomechanical stiffness³.

As proteolytic enzymes can degrade ECM, their potential contribution to KC pathogenesis has been examined in several investigations, discussed in detail in the following paragraphs, using three main approaches: biochemical analysis of conditioned media from keratocyte cultures, immunohistochemical analysis of corneal tissue, and proteomics analysis of tear fluids. Most recent studies have focussed on overall MMP protein level, without differentiating between the active forms and the inactive zymogens. However, earlier biochemical studies have looked at enzymatic activity, showing a general increase of gelatinolysis and collagenolysis^{34,35} in KC, accompanied by raised levels of the active forms of some MMPs³⁶. This is consistent with the increase in collagen degradation products measured in the tears of KC patients³⁷, pointing to an overall imbalance of proteolysis in KC. Nevertheless, as detailed below, studies on specific MMPs have shown contrasting results, possibly due to the different methodologies used and the small sample sizes in some of the investigations.

MMP-9 (also known as gelatinase B) is one of the most investigated MMPs in relation to KC. Studies of tear composition have shown that levels of MMP-9 protein are raised in KC, with up to 10-fold upregulation in patients compared to controls³⁸⁻⁴⁰. One study also reported correlation of MMP-9 protein level with severity of the disease³⁸. Interestingly, in a patient with asymmetrical KC affecting only one eye, MMP-9 was upregulated only in tears from the affected eye³⁹. In another study, elevated tear levels of MMP-9 protein were detected in 90% of eyes with confirmed KC but also in 83% of eyes with subclinical disease, suggesting that MMP-9 in tear fluid may be a useful pre-symptomatic diagnostic marker in at-risk individuals⁴¹. Pahuja *et al.* found that MMP-9 mRNA levels in KC patients were significantly higher in cells from the cone apex than in those from the corneal periphery, which may be contributing to a focal structural weakness of the cornea⁴². Shetty and colleagues confirmed that the upregulation of MMP-9 in tears of KC patients is accompanied by a significant upregulation of MMP-9 mRNA in their corneal epithelium⁴⁰. In another study, an increase in MMP-9 protein level was also detected in the blood of KC patients compared with controls⁴³. Higher levels of MMP-9 were found in tears of KC patients with allergies compared with KC patients without allergies, with the disease significantly progressing only in the first group of patients at a 12 month follow up⁴⁴. However, other studies found no significant difference in the

level of MMP-9 in the tears of patients with sub-clinical³⁹ or diagnosed^{35,45} KC compared to controls, or in KC corneas compared with normal corneal tissue^{46,47}.

MMP-2 (also known as gelatinase A) has also been intensively studied in KC, but with more conflicting results. Experiments using keratocytes in culture have shown an increase in MMP-2 activity in keratoconic compared with control corneal keratocytes in one study⁴⁸ but not in another³⁴. Upregulation of the MMP-2 activator, MMP-14 (also called MT1-MMP), but not MMP-2 itself, was also reported in KC corneas compared with normal corneas in one study⁴⁹. However, another investigation on corneal tissue detected no upregulation of MMP-2 and MMP-14 proteins in KC corneas⁵⁰. Two studies comparing tears of KC patients and controls found no significant change in the level of MMP-2^{35,45}, consistent with results from other groups showing no difference in protein expression between KC and normal corneal tissue^{46,47,51}. However, Ortak and colleagues⁵² found that plasma MMP-2 levels were lower in KC patients than controls.

Several studies suggest an increase in expression of MMP-1 in KC^{35,45,47,50,53}. Pannebaker *et al.* (2010) found no expression of MMP-1 in tears of normal controls and a significant upregulation in patients with KC⁴⁵. The increase in MMP-1 levels in tears from KC patients was independently verified by Balasubramanian *et al.*³⁵. Interestingly, in their investigation the levels of MMP-1 in KC patients who had received CXL treatment were intermediate between levels in control and KC groups³⁵. A slight upregulation of MMP-1 protein in KC corneal tissue was also detected in two other studies^{50,53}, but in contrast one earlier investigation found no overexpression⁴⁷.

Other MMPs have also been investigated in relation to KC, with contrasting outcomes. Balasubramanian *et al.* found upregulation of MMP-3, -7, and -13 proteins in tears from KC patients³⁵, in conflict with an earlier study, which did not detect any significant difference in the tear expression of MMP-3 and -13 in KC eyes⁴⁵. Another investigation also found no difference in MMP-3 protein expression between KC and normal corneal tissue⁴⁷. Furthermore, no increase in MMP-3 expression was measured in cultures of keratoconic compared with normal keratocytes³⁴. However, a moderate increase in MMP-13 protein was also reported in KC corneal tissue⁵⁰.

A number of mRNA expression^{54,55} and RNAseq⁵⁶⁻⁵⁸ studies have recently been published comparing RNA profiles in cornea from KC and control patients. These studies have some significant limitations as KC tissue is usually collected fresh from patients undergoing keratoplasty for KC, whilst control tissue is generally collected post-mortem or from patients undergoing corneal surgery for other eye diseases. Thus gene expression in controls may not be representative of fresh or healthy

cornea. In addition, control patients in these studies are generally significantly older than KC patients. Nevertheless, results of three of these studies confirm a dysregulation of the corneal proteolytic balance in KC, as they detected a downregulation of TIMP-1⁵⁵⁻⁵⁷, TIMP-2^{55,57} and TIMP-3^{56,57}. The other two studies^{54,58}, however, found no difference in TIMPs expression between tissue of KC and control myopia patients, with the caveat that only the epithelial layer of the cornea was used in one of them⁵⁸. No changes were observed in MMPs expression levels in these investigations, except for downregulation of MMP-9 in a small study⁵⁵.

Overall these data suggest a general dysregulation of proteolysis in KC patients, with an increase in level of some MMPs, particularly MMP-1 and MMP-9, confirmed in multiple independent studies. However, findings regarding the upregulation of specific MMPs were not consistently replicated across all studies.

3. MMP upregulation, corneal damage and keratoconus

MMPs play a key role in corneal repair²⁷. Corneal healing involves several coordinated steps, including migration to close the wound, proliferation to replace the lost cells, re-stratification and differentiation, and stromal remodelling to return corneal clarity^{30,59}. Upregulation of MMP-1, -2, -3, -7, -9, -12, -13 and -14 is detected during the healing of rabbit and rat corneas⁶⁰⁻⁶³, with most studies focussing on MMP-1, MMP-2 and MMP-9. After induction of a superficial wound in rabbit eyes, strong MMP-1 protein expression is detected at the leading edge of migrating epithelial cells, suggesting a function in cell motility⁶⁰. Indeed, inhibition of MMP-1 in *in-vitro* and *ex-vivo* human models of corneal healing significantly halts wound closure⁶⁴. In animal models, a low basal expression of MMP-2 protein is observed in normal undamaged corneas, but its level increases in the stroma during healing and persists above baseline for several months after wounding, suggesting a long-term role in the stromal collagen fibril remodelling that follows wound closure⁴⁶. In similar animal experiments, expression of MMP-9 protein is undetectable in undamaged cornea but observed in both the stromal and epithelial layers soon after injury^{46,62}. However MMP-9 expression only persists for a few weeks after wound closure⁴⁶. Blocking MMP-9 activity results in increased corneal wound closure in a human *in-vitro* scratch-wound assay⁶⁴ and MMP-9 deficient mice have a faster rate of corneal re-epithelialisation⁶⁵, possibly due to a dual inhibitory effect of MMP-9 on corneal cell proliferation and migration. On the other hand, remodelling of the provisional ECM deposited during corneal wound healing is defective in MMP-9 deficient mice, resulting in prolonged cornea clouding⁶⁵. In human eye diseases, over-expression of MMPs, particularly the active forms of

MMP-2 and MMP-9, has been linked to disruption of the basement membrane and the pathogenesis of corneal ulcerations and erosions^{66,67}. Therefore, a fine balance in the expression of MMPs appears necessary for maintaining the integrity and transparency of the cornea and for its correct healing.

Several studies indicate a link between contact lens wearing or eye rubbing and altered MMP expression in KC patients. For example, changes in MMP tear protein profiles have been shown in KC patients wearing contact lenses^{68,69}. In one study, temporary MMP-9 upregulation in tears was associated with contact lens wear in subjects who had not worn contact lenses before, but this increase was measured only after very extensive wearing which included nights, and it was reversed after a month of wearing⁷⁰. In another investigation in 26 KC patients, a significant increase in MMP-9 level in tears was measured after wearing scleral lenses for an average of 8 hrs⁷¹. A further study showed an increase in MMP-13 in tears from healthy volunteers after 60 seconds of eye-rubbing⁷².

Overall, this evidence provides support for the hypothesis that upregulation of MMPs in KC patients could be triggered by the corneal damage resulting from contact lens wearing or eye rubbing, two of the risk factors for KC^{19,20,22}. A certain degree of MMP-driven ECM remodelling may be a necessary step for cornea healing, but an imbalance in this tightly regulated process may, in the long term, result in the progressive weakening of the cornea (Figure 2).

4. MMP upregulation, inflammation and keratoconus

Eye rubbing and contact lens wearing have a clear link with ocular surface inflammation^{73,74}. Although KC is generally considered a non-inflammatory eye condition², this is still under debate⁷⁵⁻⁷⁷. Elevated MMP expression in tears or corneal cell cultures is observed in other corneal diseases associated with auto-immunity, infection and inflammation, such as rheumatoid arthritis with active ocular disease, herpetic eye disease, fungal keratitis and dry eye disease^{78,79}, raising the possibility that inflammation caused by eye rubbing and/or contact lens wearing may be driving the increased proteolysis observed in KC. Indeed, the upregulation of MMP-1 and MMP-9 in KC corneas, and the increase in MMP-13 observed in tears of healthy volunteers after eye-rubbing are accompanied by an increase in the level of inflammatory markers, such as IL-6 and TNF- α ^{42,72}. Plasma levels of IL-1 β , IL-6 and TNF- α are also increased in KC patients compared with controls⁴³. TNF stimulation of both normal and KC corneal fibroblasts was found to upregulate IL-6, which in turn led to an increase in

MMP-1 mRNA and protein expression in these cells⁸⁰. MMP-9 mRNA, protein and overall activity levels in corneal epithelial cells *in-vitro* is stimulated by treatment with TGF- β , IL-1 β and TNF- α ^{36,40,81}, and induction of both MMP-9 and MMP-1 mRNAs can be initiated by platelet-activating factor (PAF), an important inflammatory mediator which accumulates in the cornea following an injury⁸².

Based on this evidence, a causative link can be hypothesized between inflammation due to mechanical trauma resulting from contact lens wearing or/and eye rubbing and the increased MMP production observed in KC (Figure 2), although this area needs further investigation.

5. Genetic associations between MMP and KC

As KC is thought to have a genetic component, mutations in the coding region of MMPs or TIMPs or promoter variants altering their expression could contribute to disease risk.

An association between KC and a region on chromosome 20q12, to which the *MMP-9* gene maps, was found in a small study in an Australian population. However, linkage with the nearby *MMP-9* gene was excluded in that study⁸³. In contrast, a case-control study in an Iranian population found a significant association between KC and the *MMP-9* polymorphism rs17576⁸⁴. Interestingly, the rs17576 *MMP-9* polymorphism has also been associated with risk of glaucoma^{85,86}, with the A allele protective in both conditions. This common polymorphism (NM_004994.2, c.855A->G) causes a p.Gln279Arg change in the catalytic domain of the enzyme, which may alter its ability to bind to substrate⁸⁷. The frequency of the G allele varies from 0.74 to 0.22 depending on the ethnicity, with the highest frequencies in East and South Asians, the lowest in Latinos and an intermediate frequency in Europeans (<http://exac.broadinstitute.org/>, <https://www.ncbi.nlm.nih.gov/projects/SNP/>), which is consistent with the different risk of KC in these populations. This association therefore warrants further confirmation in other KC patient cohorts. The same investigation also found an association between the *TIMP-1* rs6609533 polymorphism and KC risk. This common change (XM_017029766.1, c.1030A->G) causes a p.Thr219Ala substitution, and the AA genotype was associated with increased KC risk in female patients only (OR = 2.27, 95% CI = 1.06–4.76, P = 0.036).

Overall, genetic association studies in KC have to date found some weak evidence for the involvement of *MMP* and *TIMP* genes. Only a handful of reports on the contribution of *MMP* and *TIMP* polymorphisms to KC risk have been published, and this is therefore another area deserving further investigation.

6. Clinical implications

The emerging role of MMPs in corneal healing and degradation could have important clinical implications for the treatment of KC. Contact and scleral lenses are the first choice treatment in the initial stages of KC, but they have been shown to alter the MMP composition of tear fluids^{70,71}, raising the possibility that they may also contribute to the progression of the disease. In a recent study, maintaining 3D cultures of KC-derived corneal fibroblasts in hypoxic conditions to simulate the low-oxygen environment associated with contact lens wearing, resulted in a decrease of collagen I secretion and ECM thickness, accompanied by upregulation of MMP-1 and -2⁸⁸. No change in MMP-3, -9, or -13 was observed. Interestingly, in two independent studies CXL treatment of keratocytes and corneal fibroblasts *in vitro* was associated with a decrease in the expression of inflammatory biomarkers and MMP-1, MMP-2, MMP-3 and MMP-9^{89,90}, with MMP-9 downregulation reported by both studies. Cross-linked collagen was also found to be resistant to degradation by MMP-1, -2, -9, and -13 in an *ex-vivo* model using bovine corneas⁹¹. These findings suggest possible mechanisms by which CXL slows KC progression. In view of the accumulating evidence for a role of MMP-9 in KC, the safety of current medications for other eye conditions, such as Latanoprost, used for glaucoma, and doxycycline, used for ocular diseases involving infection and inflammation, may need to be reviewed in keratoconus patients, as they have been shown to respectively increase and decrease MMP-9 expression^{36,92}. Interestingly, Cyclosporine A, which has been approved for the treatment of dry eye disease, another ocular condition linked to raised MMP-9⁹³, was found to reduce the expression of inflammatory markers and MMP-9 in corneal epithelial cells *in-vitro*⁴⁰. In a pilot study, 20 KC patients using regular cyclosporine eye drops for 6 months showed a significant reduction of MMP-9 levels in their tears and a trend towards a reduced progression of the disease⁴⁰. Based on these promising results, a larger clinical trial is currently under way (NCT01746823). A point-of-care test is available to quickly measure MMP-9 level in tears⁹⁴ and this would facilitate quick identification of patients who could benefit from this treatment.

7. Conclusion and perspectives

During the past decades evidence of a role for ECM degrading enzymes in KC has arisen in the literature. A number of MMPs are upregulated in KC tissue and tears, possibly due to inflammation triggered by repeated physical trauma, with the strongest evidence for a role in KC development implicating MMP-9. As specific MMP inhibitors are in development⁹⁵, this information could

potentially drive the discovery of new treatments for KC. Future investigations should confirm the functional role of specific MMPs in KC and explore genetic association between common *MMP* variants and risk of the disease.

References

1. Khaled ML, Helwa I, Drewry M, et al. Molecular and Histopathological Changes Associated with Keratoconus. *Biomed Res Int*. 2017; 2017: 7803029. 10.1155/2017/7803029.
2. Krachmer JH, Feder RS, Belin MW. Keratoconus and related noninflammatory corneal thinning disorders. *Surv Ophthalmol*. 1984; 28: 293-322.
3. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus. *Am J Ophthalmol*. 2003; 135: 620-627.
4. Parker JS, van Dijk K, Melles GR. Treatment options for advanced keratoconus: A review. *Surv Ophthalmol*. 2015; 60: 459-480. 10.1016/j.survophthal.2015.02.004.
5. Magalhaes OA, Marafon SB, Ferreira RC. Gender differences in keratoconus keratoplasty: a 25-year study in Southern Brazil and global perspective. *Int Ophthalmol*. 2018; 38: 1627-1633. 10.1007/s10792-017-0634-z.
6. Keenan TD, Jones MN, Rushton S, et al. Trends in the indications for corneal graft surgery in the United Kingdom: 1999 through 2009. *Arch Ophthalmol*. 2012; 130: 621-628. 10.1001/archophthalmol.2011.2585.
7. Matthaei M, Sandhaeger H, Hermel M, et al. Changing Indications in Penetrating Keratoplasty: A Systematic Review of 34 Years of Global Reporting. *Transplantation*. 2017; 101: 1387-1399. 10.1097/TP.0000000000001281.
8. Sarezky D, Orlin SE, Pan W, et al. Trends in Corneal Transplantation in Keratoconus. *Cornea*. 2017; 36: 131-137. 10.1097/ICO.0000000000001083.
9. Olivares Jimenez JL, Guerrero Jurado JC, Bermudez Rodriguez FJ, et al. Keratoconus: age of onset and natural history. *Optom Vis Sci*. 1997; 74: 147-151.
10. Al-Amri AM. Prevalence of Keratoconus in a Refractive Surgery Population. *J Ophthalmol*. 2018; 2018: 5983530. 10.1155/2018/5983530.
11. Rabinowitz YS. Keratoconus. *Surv Ophthalmol*. 1998; 42: 297-319.
12. Georgiou T, Funnell CL, Cassels-Brown A, et al. Influence of ethnic origin on the incidence of keratoconus and associated atopic disease in Asians and white patients. *Eye (Lond)*. 2004; 18: 379-383. 10.1038/sj.eye.6700652.
13. Pearson AR, Soneji B, Sarvananthan N, et al. Does ethnic origin influence the incidence or severity of keratoconus? *Eye (Lond)*. 2000; 14 (Pt 4): 625-628. 10.1038/eye.2000.154.
14. Gokhale NS. Epidemiology of keratoconus. *Indian J Ophthalmol*. 2013; 61: 382-383. 10.4103/0301-4738.116054.
15. Wheeler J, Hauser MA, Afshari NA, et al. The Genetics of Keratoconus: A Review. *Reprod Syst Sex Disord*. 2012. 10.4172/2161-038X.S6-001.
16. Davidson AE, Hayes S, Hardcastle AJ, et al. The pathogenesis of keratoconus. *Eye (Lond)*. 2014; 28: 189-195. 10.1038/eye.2013.278.
17. Bykhovskaya Y, Margines B, Rabinowitz YS. Genetics in Keratoconus: where are we? *Eye Vis (Lond)*. 2016; 3: 16. 10.1186/s40662-016-0047-5.
18. Karolak JA, Gajecka M. Genomic strategies to understand causes of keratoconus. *Mol Genet Genomics*. 2017; 292: 251-269. 10.1007/s00438-016-1283-z.

19. Macsai MS, Varley GA, Krachmer JH. Development of keratoconus after contact lens wear. Patient characteristics. *Arch Ophthalmol*. 1990; 108: 534-538.
20. Phillips CI. Contact lenses and corneal deformation: cause, correlate or co-incidence? *Acta Ophthalmol (Copenh)*. 1990; 68: 661-668.
21. McMonnies CW. Mechanisms of rubbing-related corneal trauma in keratoconus. *Cornea*. 2009; 28: 607-615. 10.1097/ICO.0b013e318198384f.
22. Sugar J, Macsai MS. What causes keratoconus? *Cornea*. 2012; 31: 716-719. 10.1097/ICO.0b013e31823f8c72.
23. Zadnik K, Barr JT, Edrington TB, et al. Baseline findings in the Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study. *Invest Ophthalmol Vis Sci*. 1998; 39: 2537-2546.
24. Weed KH, MacEwen CJ, Giles T, et al. The Dundee University Scottish Keratoconus study: demographics, corneal signs, associated diseases, and eye rubbing. *Eye (Lond)*. 2008; 22: 534-541. 10.1038/sj.eye.6702692.
25. Cristina Kenney M, Brown DJ. The cascade hypothesis of keratoconus. *Cont Lens Anterior Eye*. 2003; 26: 139-146. 10.1016/S1367-0484(03)00022-5.
26. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. *Nat Rev Mol Cell Biol*. 2007; 8: 221-233. 10.1038/nrm2125.
27. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. *Prog Retin Eye Res*. 2002; 21: 1-14.
28. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol*. 2004; 4: 617-629. 10.1038/nri1418.
29. Amar S, Smith L, Fields GB. Matrix metalloproteinase collagenolysis in health and disease. *Biochim Biophys Acta*. 2017; 1864: 1940-1951. 10.1016/j.bbamcr.2017.04.015.
30. Torricelli AA, Wilson SE. Cellular and extracellular matrix modulation of corneal stromal opacity. *Exp Eye Res*. 2014; 129: 151-160. 10.1016/j.exer.2014.09.013.
31. Chen S, Mienaltowski MJ, Birk DE. Regulation of corneal stroma extracellular matrix assembly. *Exp Eye Res*. 2015; 133: 69-80. 10.1016/j.exer.2014.08.001.
32. Torricelli AA, Singh V, Santhiago MR, et al. The corneal epithelial basement membrane: structure, function, and disease. *Invest Ophthalmol Vis Sci*. 2013; 54: 6390-6400. 10.1167/iovs.13-12547.
33. Chaerkady R, Shao H, Scott SG, et al. The keratoconus corneal proteome: loss of epithelial integrity and stromal degeneration. *J Proteomics*. 2013; 87: 122-131. 10.1016/j.jprot.2013.05.023.
34. Kenney MC, Chwa M, Opbroek AJ, et al. Increased gelatinolytic activity in keratoconus keratocyte cultures. A correlation to an altered matrix metalloproteinase-2/tissue inhibitor of metalloproteinase ratio. *Cornea*. 1994; 13: 114-124.
35. Balasubramanian SA, Mohan S, Pye DC, et al. Proteases, proteolysis and inflammatory molecules in the tears of people with keratoconus. *Acta Ophthalmol*. 2012; 90: e303-309. 10.1111/j.1755-3768.2011.02369.x.
36. Li DQ, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 production by human corneal epithelial cells. *Exp Eye Res*. 2001; 73: 449-459. 10.1006/exer.2001.1054.
37. Abalain JH, Dossou H, Colin J, et al. Levels of collagen degradation products (telopeptides) in the tear film of patients with keratoconus. *Cornea*. 2000; 19: 474-476.
38. Lema I, Duran JA. Inflammatory molecules in the tears of patients with keratoconus. *Ophthalmology*. 2005; 112: 654-659. 10.1016/j.optha.2004.11.050.
39. Lema I, Sobrino T, Duran JA, et al. Subclinical keratoconus and inflammatory molecules from tears. *Br J Ophthalmol*. 2009; 93: 820-824. 10.1136/bjo.2008.144253.
40. Shetty R, Ghosh A, Lim RR, et al. Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. *Invest Ophthalmol Vis Sci*. 2015; 56: 738-750. 10.1167/iovs.14-14831.

41. Zilfyan A, Abovyan A. A New Approach to Keratoconus Diagnostics Using Matrix Metalloproteinase-9 Marker. *Georgian Med News*. 2017;20-24.
42. Pahuja N, Kumar NR, Shroff R, et al. Differential Molecular Expression of Extracellular Matrix and Inflammatory Genes at the Corneal Cone Apex Drives Focal Weakening in Keratoconus. *Invest Ophthalmol Vis Sci*. 2016; 57: 5372-5382. 10.1167/iovs.16-19677.
43. Sobrino T, Regueiro U, Malfeito M, et al. Higher Expression of Toll-Like Receptors 2 and 4 in Blood Cells of Keratoconus Patients. *Sci Rep*. 2017; 7: 12975. 10.1038/s41598-017-13525-7.
44. Mazzotta C, Traversi C, Mellace P, et al. Keratoconus Progression in Patients With Allergy and Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test. *Eye Contact Lens*. 2018; 44 Suppl 2: S48-S53. 10.1097/ICL.0000000000000432.
45. Pannebaker C, Chandler HL, Nichols JJ. Tear proteomics in keratoconus. *Mol Vis*. 2010; 16: 1949-1957.
46. Fini ME, Girard MT, Matsubara M. Collagenolytic/gelatinolytic enzymes in corneal wound healing. *Acta Ophthalmol Suppl*. 1992;26-33.
47. Zhou L, Sawaguchi S, Twining SS, et al. Expression of degradative enzymes and protease inhibitors in corneas with keratoconus. *Invest Ophthalmol Vis Sci*. 1998; 39: 1117-1124.
48. Smith VA, Easty DL. Matrix metalloproteinase 2: involvement in keratoconus. *Eur J Ophthalmol*. 2000; 10: 215-226.
49. Collier SA, Madigan MC, Penfold PL. Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) and MMP-2 in normal and keratoconus corneas. *Curr Eye Res*. 2000; 21: 662-668.
50. Mackiewicz Z, Maatta M, Stenman M, et al. Collagenolytic proteinases in keratoconus. *Cornea*. 2006; 25: 603-610. 10.1097/01.icc.0000208820.32614.00.
51. Fini ME, Yue BY, Sugar J. Collagenolytic/gelatinolytic metalloproteinases in normal and keratoconus corneas. *Curr Eye Res*. 1992; 11: 849-862.
52. Ortak H, Sogut E, Tas U, et al. The relation between keratoconus and plasma levels of MMP-2, zinc, and SOD. *Cornea*. 2012; 31: 1048-1051. 10.1097/ICO.0b013e318254c028.
53. Seppala HP, Maatta M, Rautia M, et al. EMMPRIN and MMP-1 in keratoconus. *Cornea*. 2006; 25: 325-330. 10.1097/01.icc.0000183534.22522.39.
54. Mace M, Galiacy SD, Erraud A, et al. Comparative transcriptome and network biology analyses demonstrate antiproliferative and hyperapoptotic phenotypes in human keratoconus corneas. *Invest Ophthalmol Vis Sci*. 2011; 52: 6181-6191. 10.1167/iovs.10-70981.
55. Bykhovskaya Y, Gromova A, Makarenkova HP, et al. Abnormal regulation of extracellular matrix and adhesion molecules in corneas of patients with keratoconus. *Int J Keratoconus Ectatic Corneal Dis*. 2016; 5: 63-70. 10.5005/jp-journals-10025-1123.
56. Khaled ML, Bykhovskaya Y, Yablonski SER, et al. Differential Expression of Coding and Long Noncoding RNAs in Keratoconus-Affected Corneas. *Invest Ophthalmol Vis Sci*. 2018; 59: 2717-2728. 10.1167/iovs.18-24267.
57. Kabza M, Karolak JA, Rydzanicz M, et al. Collagen synthesis disruption and downregulation of core elements of TGF-beta, Hippo, and Wnt pathways in keratoconus corneas. *Eur J Hum Genet*. 2017; 25: 582-590. 10.1038/ejhg.2017.4.
58. You J, Corley SM, Wen L, et al. RNA-Seq analysis and comparison of corneal epithelium in keratoconus and myopia patients. *Sci Rep*. 2018; 8: 389. 10.1038/s41598-017-18480-x.
59. Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. *Prog Retin Eye Res*. 2015; 49: 17-45. 10.1016/j.preteyeres.2015.07.002.
60. Mulholland B, Tuft SJ, Khaw PT. Matrix metalloproteinase distribution during early corneal wound healing. *Eye (Lond)*. 2005; 19: 584-588. 10.1038/sj.eye.6701557.
61. Ye HQ, Azar DT. Expression of gelatinases A and B, and TIMPs 1 and 2 during corneal wound healing. *Invest Ophthalmol Vis Sci*. 1998; 39: 913-921.

62. Ye HQ, Maeda M, Yu FS, et al. Differential expression of MT1-MMP (MMP-14) and collagenase III (MMP-13) genes in normal and wounded rat corneas. *Invest Ophthalmol Vis Sci.* 2000; 41: 2894-2899.
63. Lyu J, Joo CK. Wnt-7a up-regulates matrix metalloproteinase-12 expression and promotes cell proliferation in corneal epithelial cells during wound healing. *J Biol Chem.* 2005; 280: 21653-21660. 10.1074/jbc.M500374200.
64. Daniels JT, Limb GA, Saarialho-Kere U, et al. Human corneal epithelial cells require MMP-1 for HGF-mediated migration on collagen I. *Invest Ophthalmol Vis Sci.* 2003; 44: 1048-1055.
65. Mohan R, Chintala SK, Jung JC, et al. Matrix metalloproteinase gelatinase B (MMP-9) coordinates and effects epithelial regeneration. *J Biol Chem.* 2002; 277: 2065-2072. 10.1074/jbc.M107611200.
66. Sakimoto T, Sawa M. Metalloproteinases in corneal diseases: degradation and processing. *Cornea.* 2012; 31 Suppl 1: S50-56. 10.1097/ICO.0b013e318269ccd0.
67. Garrana RM, Zieske JD, Assouline M, et al. Matrix metalloproteinases in epithelia from human recurrent corneal erosion. *Invest Ophthalmol Vis Sci.* 1999; 40: 1266-1270.
68. Fodor M, Kolozsvari BL, Petrovski G, et al. Effect of contact lens wear on the release of tear mediators in keratoconus. *Eye Contact Lens.* 2013; 39: 147-152. 10.1097/ICL.0b013e318273b35f.
69. Lema I, Duran JA, Ruiz C, et al. Inflammatory response to contact lenses in patients with keratoconus compared with myopic subjects. *Cornea.* 2008; 27: 758-763. 10.1097/ICO.0b013e31816a3591.
70. Markoulli M, Papas E, Cole N, et al. Effect of contact lens wear on the diurnal profile of matrix metalloproteinase 9 in tears. *Optom Vis Sci.* 2013; 90: 419-429. 10.1097/OPX.0b013e31828d7d3b.
71. Carracedo G, Blanco MS, Martin-Gil A, et al. Short-term Effect of Scleral Lens on the Dry Eye Biomarkers in Keratoconus. *Optom Vis Sci.* 2016; 93: 150-157. 10.1097/OPX.0000000000000788.
72. Balasubramanian SA, Pye DC, Willcox MD. Effects of eye rubbing on the levels of protease, protease activity and cytokines in tears: relevance in keratoconus. *Clin Exp Optom.* 2013; 96: 214-218. 10.1111/cxo.12038.
73. Chao C, Richdale K, Jalbert I, et al. Non-invasive objective and contemporary methods for measuring ocular surface inflammation in soft contact lens wearers - A review. *Cont Lens Anterior Eye.* 2017; 40: 273-282. 10.1016/j.clae.2017.05.008.
74. Greiner JV, Peace DG, Baird RS, et al. Effects of eye rubbing on the conjunctiva as a model of ocular inflammation. *Am J Ophthalmol.* 1985; 100: 45-50.
75. Galvis V, Sherwin T, Tello A, et al. Keratoconus: an inflammatory disorder? *Eye (Lond).* 2015; 29: 843-859. 10.1038/eye.2015.63.
76. Ionescu C, Corbu CG, Tanase C, et al. Inflammatory Biomarkers Profile as Microenvironmental Expression in Keratoconus. *Dis Markers.* 2016; 2016: 1243819. 10.1155/2016/1243819.
77. McMonnies CW. Inflammation and keratoconus. *Optom Vis Sci.* 2015; 92: e35-41. 10.1097/OPX.0000000000000455.
78. Smith VA, Rishmawi H, Hussein H, et al. Tear film MMP accumulation and corneal disease. *Br J Ophthalmol.* 2001; 85: 147-153.
79. Rohini G, Murugeswari P, Prajna NV, et al. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis. *Cornea.* 2007; 26: 207-211. 10.1097/01.ico.0000248384.16896.7d.
80. Du G, Liu C, Li X, et al. Induction of matrix metalloproteinase-1 by tumor necrosis factor-alpha is mediated by interleukin-6 in cultured fibroblasts of keratoconus. *Exp Biol Med (Maywood).* 2016; 241: 2033-2041. 10.1177/1535370216650940.


81. Gordon GM, Ledee DR, Feuer WJ, et al. Cytokines and signaling pathways regulating matrix metalloproteinase-9 (MMP-9) expression in corneal epithelial cells. *J Cell Physiol.* 2009; 221: 402-411. 10.1002/jcp.21869.
82. Ottino P, Taheri F, Bazan HE. Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: imbalance between the gene expression of MMP-9 and TIMP-1 and -2. *Exp Eye Res.* 2002; 74: 393-402. 10.1006/exer.2001.1135.
83. Fullerton J, Paprocki P, Foote S, et al. Identity-by-descent approach to gene localisation in eight individuals affected by keratoconus from north-west Tasmania, Australia. *Hum Genet.* 2002; 110: 462-470. 10.1007/s00439-002-0705-7.
84. Saravani R, Yari D, Saravani S, et al. Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus. *Jpn J Ophthalmol.* 2017; 61: 218-222. 10.1007/s10384-017-0503-3.
85. Wu MY, Wu Y, Zhang Y, et al. Associations between matrix metalloproteinase gene polymorphisms and glaucoma susceptibility: a meta-analysis. *BMC Ophthalmol.* 2017; 17: 48. 10.1186/s12886-017-0442-2.
86. Zhang Y, Wang M, Zhang S. Association of MMP-9 Gene Polymorphisms with Glaucoma: A Meta-Analysis. *Ophthalmic Res.* 2016; 55: 172-179. 10.1159/000443627.
87. Hu Z, Huo X, Lu D, et al. Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. *Clin Cancer Res.* 2005; 11: 5433-5439. 10.1158/1078-0432.CCR-05-0311.
88. McKay TB, Hjortdal J, Priyadarsini S, et al. Acute hypoxia influences collagen and matrix metalloproteinase expression by human keratoconus cells in vitro. *PLoS One.* 2017; 12: e0176017. 10.1371/journal.pone.0176017.
89. Andrade FEC, Covre JL, Ramos L, et al. Evaluation of galectin-1 and galectin-3 as prospective biomarkers in keratoconus. *Br J Ophthalmol.* 2018; 102: 700-707. 10.1136/bjophthalmol-2017-311495.
90. Sharif R, Fowler B, Karamichos D. Collagen cross-linking impact on keratoconus extracellular matrix. *PLoS One.* 2018; 13: e0200704. 10.1371/journal.pone.0200704.
91. Zhang Y, Mao X, Schwend T, et al. Resistance of corneal RFUVA-cross-linked collagens and small leucine-rich proteoglycans to degradation by matrix metalloproteinases. *Invest Ophthalmol Vis Sci.* 2013; 54: 1014-1025. 10.1167/iovs.12-11277.
92. Honda N, Miyai T, Nejima R, et al. Effect of latanoprost on the expression of matrix metalloproteinases and tissue inhibitor of metalloproteinase 1 on the ocular surface. *Arch Ophthalmol.* 2010; 128: 466-471. 10.1001/archophthalmol.2010.40.
93. Lanza NL, Valenzuela F, Perez VL, et al. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye. *Ocul Surf.* 2016; 14: 189-195. 10.1016/j.jtos.2015.10.004.
94. Sambursky R, Davitt WF, 3rd, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. *JAMA Ophthalmol.* 2013; 131: 24-28. 10.1001/jamaophthalmol.2013.561.
95. Cathcart JM, Cao J. MMP Inhibitors: Past, present and future. *Front Biosci (Landmark Ed).* 2015; 20: 1164-1178.


Figure Legends

Figure 1. Sagittal cross-section of the human cornea after staining with haematoxylin and eosin. The epithelium, Bowman's layer, stroma, Descemet's membrane and endothelium are shown (Image courtesy of Mr Mike Shires, Leeds Institute of Cancer & Pathology, University of Leeds).

Figure 2. Potential mechanistic links between KC risk factors (orange) and MMP-mediated corneal weakening. Specific inflammatory molecules and specific MMPs are indicated in green.

ACCEPTED MANUSCRIPT





- Keratoconus (KC) is a corneal disease with environmental and genetic causes
- Matrix Metalloproteinases (MMPs) contribute to corneal integrity and healing
- Increased levels of some MMPs, particularly MMP-1 and MMP-9, are found in KC
- Dysregulation of MMPs may contribute to corneal weakening in KC
- Further studies in this area may drive the discovery of new treatments for KC

ACCEPTED MANUSCRIPT